[Edaily Reporter Kim Hyung-il ] ENBIOCO., LTD.(352940)announced on the 16th that it has signed a 3 billion won investment agreement with #ARIBIOLAB, a company specializing in bio-platforms.

This investment is a strategic decision aimed at expanding the R&D and commercialization capabilities for new substances—accumulated through its existing crop protection business—into new areas. ENBIOCO., LTD. believes that its R&D capabilities, which involve discovering new substances, verifying their efficacy and safety, and then proceeding through registration and commercialization, will be the core of the company’s future competitiveness.

Accordingly, ENBIOCO., LTD. plans to explore opportunities for technical and business collaboration with ARIBIOLAB—which is developing new substances and platform technologies in the pharmaceutical and biotech sectors—and to expand its business opportunities in the biotech field.

ARIBIOLAB is a company that develops vaccines and immunotherapies based on its proprietary immune-enhancing platforms, “L-pampo” and “Lipo-pam.” The company has established a diverse pipeline that includes the recombinant shingles vaccine “CVI-VZV-001,” as well as a hepatitis B vaccine and immuno-oncology drugs, and is also pursuing the development of messenger RNA (mRNA)-based vaccine candidates.

ENBIOCO., LTD. plans to use this investment as an opportunity to solidify its “Two-Track” growth strategy, which aims to simultaneously drive growth in its existing crop protection business and expand its new substance business. An ENBIOCO., LTD. official stated, “We aim to evolve beyond a company that simply manufactures and sells products into a technology and commercialization enterprise that discovers new substances and transforms them into business opportunities,” adding, “This investment in ARIBIOLAB was made as part of this mid- to long-term growth strategy.”